Jpmorgan Chase & CO Sqz Biotechnologies CO Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.16 - $3.48 $276,851 - $446,038	-128,172 Reduced 98.41%	2,075 $5,000
Q2 2022 Aug 11, 2022	BUY	$2.77 - $5.0 $36,054 - $65,080	13,016 Added 11.1%	130,247 $414,000
Q1 2022 May 11, 2022	SELL	$4.01 - $10.42 $35,616 - $92,550	-8,882 Reduced 7.04%	117,231 $564,000
Q4 2021 Feb 10, 2022	SELL	$8.93 - $14.85 $990,301 - $1.65 Million	-110,896 Reduced 46.79%	126,113 $1.13 Million
Q3 2021 Nov 12, 2021	BUY	$11.46 - $15.77 $2.72 Million - $3.74 Million	237,009 New	237,009 $3.42 Million

1.47M

Ticker SQZ
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,248,600
Market Cap $1.46M
Description
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.